Risk of autoimmune hepatitis, non-infectious gastroenteritis, and colitis among patients with metastatic clear cell renal cell carcinoma (ccRCC) treated with pembrolizumab/axitinib vs nivolumab/ipilimumab.
Authors: Allen Seylani, Yohannes Haile, Assal Sadighian
Published: 2025-05-28
DOI:
10.1200/jco.2025.43.16_suppl.e16530
Source:
Full article
Abstract
e16530